[Clinical evaluation of fludilat in cerebrovascular insufficiency].
In order to evaluate the clinical efficacy of Fludilat, we studied 75 patients, 37 women (49.3 per cent) and 38 men (50.7 per cent), with ages between 36 and 98 years, during a period of 3 months. 50 of the patients received Fludilat at the dose of three tablets per day during 3 months. The remaining 25 patients received Placebo during the same period of time. We obtained very good results in 63.5 per cent, good in 20.4 per cent and poor in 16.1 per cent of the patients treated with Fludilat. The results with Placebo were very good 2.9 per cent, good 41.8 per cent and poor 55.3 per cent. We observed no side effects during the treatment. Therefore from our study we conclude that Fludilat is an effective drug in the treatment of the disturbances produced by the cerebral vascular insufficiency.
D000328:Adult; D000368:Aged; D001537:Bencyclane / Q000627:therapeutic use*; D002561:Cerebrovascular Disorders / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003508:Cycloheptanes / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos
D003508:Cycloheptanes; D010919:Placebos; D001537:Bencyclane
Evaluación clinica del Fludilat en la insuficiencia vascular cerebral.